[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597301":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":66,"collaborators":46,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":46,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":46,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":93,"whyStopped":46,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Guadalajara","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fenugreek seed","EXPERIMENTAL","500 mg of fenugreek seed before each meal for 12 weeks",[13],"Dietary Supplement: Fenugreek seed",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","500 mg of calcined magnesia before each meal for 12 weeks",[19],"Other: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Fenugreek seed: 1500 mg per day for 12 weeks",[9],[26],"Trigonella foenum-graecum",{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo: Calcined magnesia 1500 mg per day for 12 weeks",[15],[31],"Calcined magnesia",[33],{"name":34,"affiliation":35,"role":36},"Marisol Cortez Navarrete, PhD","Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara","PRINCIPAL_INVESTIGATOR",[38],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","(33) 1058-5200","34211","marisol.cortez@academicos.udg.mx",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Instituto de Terapéutica Experimental y Clínica (INTEC), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara.",null,"Guadalajara","Jalisco","44340","Mexico","MX",{"type":53,"coordinates":54},"Point",[55,56],-103.34749,20.67738,{"lat":56,"lon":55},[59,61,65],{"name":34,"role":39,"phone":60,"phoneExt":41,"email":42},"3310585200",{"name":62,"role":39,"phone":60,"phoneExt":63,"email":64},"Karina G Pérez Rubio, PhD","34212","karina.prubio@academicos.udg.mx",{"name":34,"role":36,"phone":46,"phoneExt":46,"email":46},{"type":36,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"Marisol Cortez Navarrete","Principal investigator","100597301","effect-of-fenugreek-seed-administration-on-metabolic-syndrome-insulin-sensitivity-and-insulin-secretion-100597301",false,"NCT07056712","Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion","Effect of Fenugreek Seed Administration on the Components of Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion","Inclusion Criteria:\n\n* Men and women between 30 and 60 years old.\n* Diagnosis of Metabolic Syndrome (MS) according to the International Diabetes Federation (IDF) criteria.\n\nWaist circumference ≥90 cm in men and ≥80 cm in women, plus the presence of two or more of the following criteria:\n\n* Fasting glucose ≥100 mg\u002FdL or previous diagnosis of type 2 diabetes.\n* Systolic Blood Pressure ≥130 mmHg.\n* Diastolic Blood Pressure ≥85 mmHg.\n* Triglycerides ≥150 mg\u002FdL.\n* HDL cholesterol \\\u003C40 mg\u002FdL in men and \\\u003C50 mg\u002FdL in women.\n\n  * Body Mass Index between 25.0 and 34.9 kg\u002Fm².\n  * Stable weight during the 3 months prior to the start of the study (weight variation less than 10%).\n  * Not receiving pharmacological treatment for any component of MS, insulin sensitivity, and\u002For insulin secretion.\n  * Signed informed consent form.\n\nNon-Inclusion Criteria:\n\n* Suspected or confirmed pregnancy.\n* Breastfeeding period.\n* Fasting glucose ≥126 mg\u002FdL.\n* LDL cholesterol ≥155 mg\u002FdL.\n* Triglycerides ≥500 mg\u002FdL.\n* Systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg.\n* Use of medications and\u002For supplements known to influence the study variables.\n* History of kidney, thyroid, liver disease, or ischemic heart disease.\n* Active smoker.\n* Not using an effective and stable contraceptive method.\n\nExclusion Criteria:\n\n* Voluntary withdrawal of informed consent.\n* Treatment adherence ≤80%.\n* Occurrence of a serious adverse event.\n* Loss to follow-up.","ALL","30 Years","60 Years",{"count":80,"type":81},28,"ESTIMATED","INTERVENTIONAL",[84],"NA","Fenugreek has been shown to have beneficial effects on various metabolic abnormalities associated with metabolic syndrome (MS). However, no clinical trials have evaluated its effect on all components of MS, insulin sensitivity, and insulin secretion. Therefore, the main objective of this study is to assess the effect of fenugreek seed administration versus placebo on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.",[87],"Metabolic Syndrome",[87,89,90,91,92],"Fenugreek","Insulin Secretion","Insulin Sensitivity","Nutraceutic","NOT_YET_RECRUITING","2025-09-01",{"date":96,"type":97},"2025-09-08","ACTUAL",{"date":99,"type":81},"2025-09-15",{"date":101,"type":81},"2026-09-15",{"name":5,"class":6},1]